A Research Study Looking at Long-term Blood Sugar Control in People With Type 2 Diabetes Being Treated With Xultophy® in a Real-world Setting in Italy

Inclusion Criteria: * Informed consent obtained before any study-related activities (study-related activities include any procedure related to recording of data according to the protocol). * Male or female, age greater than or equal to 18 years at the time of signing informed consent. * Patient diagnosed with T2D greater than or equal to 12 months prior to signing informed consent. * The decision to initiate treatment with commercially available Xultophy® has been made by the patient and the treating physician before and independently from the decision to participate in this study. * Treated with basal insulin with or without use of oral antidiabetics (OADs), with or without use of bolus insulin prior to initiating Xultophy®. * For patients transferring from a regimen including bolus insulin, upon initiation of Xultophy® the bolus insulin component of the treatment regimen was stopped. * The patient initiated Xultophy® treatment for at least 2 months, but no more than 3 months prior to signing informed consent. * Available and documented HbA1c measurement no more than 3 months prior to Xultophy® initiation. Exclusion Criteria: * Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation. * Diagnosed with type 1 diabetes mellitus, maturity-onset diabetes of the young, latent autoimmune diabetes in adults, gestational diabetes or any hyperglycaemic state other than T2D. * Women known to be pregnant or breastfeeding, or women planning to become pregnant during the conduct of the study. * Previous participation in this study. Participation is defined as having given informed consent in this study. * Participation in another T2D clinical study that involves any clinical intervention or administration of an investigational drug within 3 months prior to enrolment into the study. * Any contraindications for Xultophy®, including hypersensitivity to the active substances or any of the excipients as specified in the Xultophy® local label.